Publication: Anti-infectious plants of the thai karen: A meta-analysis
Issued Date
2020-06-01
Resource Type
ISSN
20796382
Other identifier(s)
2-s2.0-85086479392
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antibiotics. Vol.9, No.6 (2020), 1-15
Suggested Citation
Methee Phumthum, Henrik Balslev Anti-infectious plants of the thai karen: A meta-analysis. Antibiotics. Vol.9, No.6 (2020), 1-15. doi:10.3390/antibiotics9060298 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/57722
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Anti-infectious plants of the thai karen: A meta-analysis
Author(s)
Other Contributor(s)
Abstract
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Pharmacology has developed many drugs to treat infections, but many people, especially in developing countries, cannot afford to purchase them, and still depend on traditional knowledge and local medicinal plants to fight off infections. In addition, numerous microbes have developed resistance to the pharmaceutical drugs developed to fight them, and for many, such as Covid-19, effective drugs remain to be found. Ethnomedicinal knowledge is useful, not only for local people as a source of medicine for primary health care, but also for new pharmacological discoveries. This study aimed to identify the plants that the Karen, the largest hill-tribe ethnic minority in northern and western Thailand, use for treatments of infectious diseases. We present a meta-analysis of data from 16 ethnobotanical studies of 25 Karen villages with the aim of understanding traditional knowledge and treatments and point to potential plants for further pharmacological development. The Karen used 127 plant species from 59 plant families to treat infections and infectious diseases. The Cultural Important Index (CI) showed that the Leguminosae, Euphorbiaceae, Asteraceae, Lauraceae, Apocynaceae, Menispermaceae, and Lamiaceae were the most commonly used families. As for species, Cleidion javanicum, Tinospora crispa, Litsea cubeba, Aesculus assamica, Tadehagi triquetrum, Senna alata, Tithonia diversifolia, Embelia sessiliflora, and Combretum indicum were the most commonly used in treatments of infectious diseases. We suggest that these plant species should be the first to be pharmacologically tested for possible development of medicines, and the remaining species registered should subsequently undergo testing.